MEDIKIT CO.,LTD.
7749・Standard Market・Precision Instruments
Business
MEDIKIT CO., LTD. is a single-segment company engaged in the development, manufacturing, and sale of medical devices specialized in the vascular and blood-related fields. Its main products consist of three lines: dialysis indwelling needles (Happy Cath ProFlex Series), IV catheters (Super Cath Series), and sheath introducers/catheters for interventional use. Manufacturing is handled by consolidated subsidiaries Togo Medikit Co., Ltd. (Miyazaki Prefecture) and Medikit Vietnam Co., Ltd. (Vietnam), while the Company sells the products to medical institutions and healthcare professionals both domestically and internationally. Net sales for FY2026 (ending March 2026) were ¥23,781 million. In addition to the domestic market, the Company is actively expanding overseas, particularly in North America, with overseas sales reaching ¥4,246 million (up 20.6% year on year).
Business Model
Through a corporate structure that separates the sales company (MEDIKIT CO., LTD.) from the manufacturing company (Togo Medikit Co., Ltd.), the roles of each entity are clarified in pursuit of growth and profitability. As the company's core products are consumables (indwelling needles, catheters, etc.) used repeatedly in medical settings, stable ongoing demand forms the foundation of earnings. The company in principle maintains debt-free management, funding working capital and capital expenditures from its own resources, with an equity ratio reaching 87.8%.
Company Strengths
The company secured the top domestic share in IV catheters through the development of safety mechanisms and pressure-hemostasis assist valves. Safety-mechanism products such as Super Cath 5 and 7 have penetrated the market, and sales of IV Catheters (Super Cath Series) in FY2026 (ending March 2026) reached ¥8,441 million (up 13.9% year on year), maintaining high growth. An export framework producing 3 million units per month for ICU Medical has also been established.
The corporate structure separates the sales company from the manufacturing company to clarify roles, and the company maintains a firm financial policy of funding working capital and capital expenditure principally from its own resources. As of the end of FY2026 (ending March 2026), the equity ratio stood at 87.8% and cash and cash equivalents reached ¥18,652 million, giving the company a financial structure highly resilient to changes in the external environment.
Since its founding in 1971, the company has accumulated technology in the vascular and blood fields, starting from the manufacture of indwelling needles for blood transfusion and infusion. It maintains an R&D staff of 43 across 7 divisions, with R&D expenses in FY2026 (ending March 2026) of ¥299 million (1.3% of net sales). The company has a track record of continuous new product development, including the application for the fully automatic biopsy needle "CORECUT FA" and the approval of the new sheath "VARIUS".
ENVALITH's Perspective
Performance Trend
Revenue rose for 5 consecutive periods, from ¥20,131 million in FY2022 (ended March 2022) to ¥23,781 million in FY2026 (ending March 2026). However, operating profit, which peaked at ¥4,678 million in FY2024 (ended March 2024), declined for 2 consecutive periods to ¥4,487 million in FY2025 (ended March 2025) and ¥4,272 million in FY2026 (ending March 2026). The main cause is increased depreciation expenses accompanying capital investment expansion (from ¥1,472 million in the previous period to ¥1,822 million in the current period); although the gross profit margin is on an improving trend, this has been offset by higher SG&A expenses. External factors, including surging raw material and energy prices and the impact of revisions to medical reimbursement fees for medical institutions, have also continued to weigh on results. Operating cash flow improved to ¥4,734 million (from ¥3,562 million in the previous period), and the cash balance increased to ¥18,652 million. For FY2027 (ending March 2027), the company plans revenue of ¥25,800 million (up 8.5%) and operating profit of ¥4,300 million (up 0.6%), anticipating that the profit margin has bottomed out.
Growth Strategy
Aiming to achieve medium-term plan targets through domestic and international sales expansion of IV catheters and Intervention Products, and penetration of new products
Continuing domestic penetration centered on the safety-mechanism-equipped indwelling needle "Super Cath 5/7" while capturing overseas demand focused primarily on North America. Achieved a 13.9% increase in FY2026 (ending March 2026), with the FY2027 (ending March 2027) plan also targeting a 12.4% increase (¥9,486 million).
Promoting expanded sales of high-value-added products such as the braided sheath for arrhythmia treatment "AbRoad STOUT" and the steerable sheath "AbRoad FLEX." Targeting a 4.9% increase (¥7,495 million) in FY2026 (ending March 2026) and an 11.0% increase (¥8,321 million) in the FY2027 (ending March 2027) plan.
The Medilizer AGD System, a cerebrovascular guidance assist device developed by Bolt Medical, received insurance reimbursement listing and began sales in March 2025. The company is currently promoting understanding of the product among healthcare professionals through classroom lectures and hands-on training. It is at the development stage as a new revenue source.
Promoting the medium-term plan targeting net sales of ¥29,000 million to ¥32,000 million in FY2029 (ending March 2029). The plan is built on three pillars: expansion and stable supply of safety-featured products, strengthening of overseas expansion, and penetration of high-value-added products, pursued as a unified group effort. Net sales of ¥23,781 million in FY2026 (ending March 2026) represent progress in the midst of plan execution.
Last updated: July 19, 2026